Regulatory GSK again pulls application for leucovorin, touted by FDA as potential autism treatment BioSpaceGSK discontinued Wellcovorin in 1999, but the FDA in September last year asked the pharma to refile an application, pointing to its potential to...RegulatoryNeuroscienceRead full story pharminent April 10, 2026 (Last updated: April 10, 2026) BioSpace GSK discontinued Wellcovorin in 1999, but the FDA in September last year asked the pharma to refile an application, pointing to its potential to… RegulatoryNeuroscienceRead full story Post navigation Previous: Roche places a $1bn bet on C4T degrader-antibody conjugatesNext: Senju launches first-in-class dry eye disease drug in Japan Related Stories Regulatory Third Circuit Affirms Denial of Stelara Biosimilar Injunction pharminent May 11, 2026 Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher pharminent May 11, 2026 Regulatory BMS’ Sotyktu secures EC approval for psoriatic arthritis pharminent May 11, 2026
